J.P. Morgan Maintains Neutral on Amicus Therapeutics (FOLD)

J.P. Morgan is out with its report today on Amicus Therapeutics

, maintaining Neutral. In a note to clients, J.P. Morgan writes, "We are Neutral on FOLD shares. Amicus' chaperone technology is a unique platform in biotech that could offer treatment for a wide range of diseases, including Fabry disease and Parkinson's disease. Longer term we think there is a good probability that Amigal for Fabry disease will be successful, and we expect other earlier stage compounds to move forward. However, we think the announcement that Plicera failed a phase 2 study in Gaucher disease was a negative announcement that may increase the discount on Amicus' technology until data from other programs are made available." At the time of posting, shares of FOLD were trading at $7.26, up 0.69% from Monday's close.